Literatura científica selecionada sobre o tema "Β-lactamases – Résistance aux antibiotiques"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Β-lactamases – Résistance aux antibiotiques".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "Β-lactamases – Résistance aux antibiotiques"
Frère, Jean-Marie. "Résistance bactérienne aux antibiotiques : le rôle prépondérant des ß-lactamases". Bulletin de la Classe des sciences 9, n.º 1 (1998): 139–46. http://dx.doi.org/10.3406/barb.1998.27895.
Texto completo da fonteCattoir, Vincent, e Sophie Reissier. "L’antibiorésistance en 2023". Revue de biologie médicale N° 373, n.º 4 (2 de março de 2023): 49–56. http://dx.doi.org/10.3917/rbm.373.0049.
Texto completo da fonteThonda, O. A., A. O. Oluduro, O. O. Adewole e P. O. Obiajunwa. "Phenotypic and genotypic characterization of plasmid-mediated AmpC beta-lactamases in enteric Gram-negative bacteria from patients with lower respiratory tract infections in a tertiary hospital, southwest Nigeria". African Journal of Clinical and Experimental Microbiology 22, n.º 4 (27 de setembro de 2021): 465–72. http://dx.doi.org/10.4314/ajcem.v22i4.6.
Texto completo da fonteRakotovao-Ravahatra, Z. D., F. M. Randriatsarafara, A. L. Rakotovao e A. Rasamindrakotroka. "Prevalence and factors associated with extended-spectrum βlactamase producing Enterobacteriaceae bacteraemia in University Hospital of Befelatanana, Madagascar". African Journal of Clinical and Experimental Microbiology 22, n.º 1 (26 de janeiro de 2021): 52–59. http://dx.doi.org/10.4314/ajcem.v22i1.7.
Texto completo da fonteJamal, W., K. Iregbu, A. Fadhli, F. Khodakhast, P. Nwajiobi-Princewill, N. Medugu e V. O. Rotimi. "A point-prevalence survey of carbapenem-resistant Enterobacteriaceae in two different cities in Kuwait and Nigeria". African Journal of Clinical and Experimental Microbiology 23, n.º 4 (23 de outubro de 2022): 358–68. http://dx.doi.org/10.4314/ajcem.v23i4.4.
Texto completo da fonteGbegbe, D. A., N. P. N'zi, S. Monthaut, N. Guessennd-Kouadio e D. M. Angaman. "Antibiotic resistance profiles of uropathogenic bacterial isolates in Haut-Sassandra Region, Côte d’Ivoire from January 2019 to December 2022". African Journal of Clinical and Experimental Microbiology 25, n.º 1 (16 de janeiro de 2024): 38–47. http://dx.doi.org/10.4314/ajcem.v25i1.5.
Texto completo da fonteBenbrahim, C., M. S. Barka, L. Benmahdi, A. Zatout e A. Khadir. "Klebsiella pneumoniae producing extended spectrum β-lactamase in Regional Military University Hospital of Oran, Algeria: antibiotic resistance, biofilm formation, and detection of blaCTX-M and blaTEM genes". African Journal of Clinical and Experimental Microbiology 22, n.º 1 (26 de janeiro de 2021): 28–37. http://dx.doi.org/10.4314/ajcem.v22i1.5.
Texto completo da fonteAdeyemi, F. M., e S. B. Akinde. "ESβL, AmpC and carbapenemase co-production in multi-drug resistant Gram-negative bacteria from HIV-infected patients in southwestern Nigeria". African Journal of Clinical and Experimental Microbiology 22, n.º 1 (26 de janeiro de 2021): 38–51. http://dx.doi.org/10.4314/ajcem.v22i1.6.
Texto completo da fonteBelmonte, O., D. Drouet, J. Alba, M. P. Moiton, B. Kuli, N. Lugagne-Delpon, C. Mourlan e M. C. Jaffar-Bandjee. "Évolution de la résistance des entérobactéries aux antibiotiques sur l’île de la Réunion : émergence des bêta-lactamases à spectre élargi". Pathologie Biologie 58, n.º 1 (fevereiro de 2010): 18–24. http://dx.doi.org/10.1016/j.patbio.2009.07.021.
Texto completo da fonteRio, Y., P. Pina, F. Jurin, P. Allouch, J. Didion, H. Chardon e D. Chiche. "Sensibilité de Pseudomonas aeruginosa aux antibiotiques, isolés chez des malades de soins intensifs français en 1998. Phénotypes de résistance aux β-lactamines. Étude ESCRIME". Pathologie Biologie 50, n.º 1 (janeiro de 2002): 12–17. http://dx.doi.org/10.1016/s0369-8114(01)00261-9.
Texto completo da fonteTeses / dissertações sobre o assunto "Β-lactamases – Résistance aux antibiotiques"
Madec, Stéphanie. "Résistance des bactéries aux antibiotiques à noyau β-lactame : mécanismes et incidences". Brest, 2001. http://www.theses.fr/2001BRES3105.
Texto completo da fonteMammeri, Hedi. "Mécanismes émergents de résistance aux antibiotiques : céphalosporinases à spectre étendu et résistance plasmidique aux quinolones". Paris 5, 2006. http://www.theses.fr/2006PA05D035.
Texto completo da fonteß-Lactams and fluoroquinolones constitute the most prescribed antibiotics used in therapeutics. Recently, two novel acquired mechanisms of resistance were described : the plasmid-borne qnrA gene, encoding a pentapeptide that prevents binding of fluoroquinolones on their targets, and the extended-spectrum AmpC ß-lactamases, which display an increased hydrolysis activity toward oxyiminocephalosporins. During this work, we have characterized several novel extended-spectrum cephalosporinases, mainly produced by Escherichia coli isolates, identified new structural modifications responsable for the extension of the hydrolysis spectrum and revealed the genetic diversity of the ampC genes in E. Coli. We have also described the emergence of the qnrA gene in Europe, the involvement of its genetic environment in its expression, the absence of effect of QnrA on the bactericidal activity of fluoroquinolones, and the origin of qnrA naturally present on the chromosome of Shewanella algae
Boutal, Hervé. "Développement et validation de tests de détection rapide de la résistance aux antibiotiques". Thesis, Université Paris-Saclay (ComUE), 2017. http://www.theses.fr/2017SACLS499/document.
Texto completo da fonteBeta-lactams are antibiotics preferentially used against gram-negative bacilli infections. The worldwide spread of extended spectrum beta-lactamases (ESBL) or carbapenemase-producing organisms is a global concern and also an economic threat.Within those organisms, Enterobacteriaceae have a major role as causes of nosocomial infections (and, for E. coli, also of community-acquired infections). The emergence and dissemination of ESBL-producing Enterobacteriaceae (ESBL-E), mainly expressing beta-lactamases from the CTX-M family, and in a worrier aspect of carbapenemase-producing Enterobacteriaceae (CPE), mainly NDM, KPC, IMP, VIM and OXA-48 like enzymes, are undoubtedly a matter of great public health concern.CTX-Ms hydrolyze broad-spectrum cephalosporins and are the most encountered BLSE in Enterobacteriaceae, and CTX-Ms producers have been reported as the most prevalent ESBL producers in community-onset urinary tract infections (UTIs). Moreover, CTX-M-producing E.coli are a major cause of bloodstream infections that are often secondary to UTIs. These severe infections are treated with carbapenems, considered as last resort antibiotics. Unfortunately, their increasing use put a selective pressure on Enterobacteriaceae, leading to more and more strains showing decreased susceptibility to carbapenems and potentially leading to therapeutic failure.Considering the limited treatment options for ESBL-E and that CPE are often resistant to several if not all classes of antibiotics, and for which very few (or no) antibiotic options remain available, their rapid detection and identification are essential. Reliable tests are needed to help physicians, to quickly provide appropriate infection control measures, to adapt rapidly antibiotic treatment and optimize care strategies and outcomes.While detecting ESBL-Es or EPCs, it is also crucial to identify the implicated beta-lactamase for accurate therapy implementation. To do so, the antibody-specificity based methods are undoubtedly appropriate. To respond to the current needs, antimicrobial drug resistance detection methods must be cheap (reduced costs of consumables and equipment) and easy to use (reduced technical complexity) for the end user, and LFIAs respond to this requirements. Our objective was to develop such tests, and this led us to produce monoclonal antibodies against CTX-Ms, NDM, KPC, IMP, VIM and OXA-48 carbapenemase families and to develop and validate the corresponding LFIAs. Our tests are robust assays, easily transferable in a commercialized version, stable for more than 24 months without refrigeration, user-friendly (no requirement of trained staff), high performance (sensitive and specific), low cost, from 7€ (monotest) to less than 15€ (multiplex). Moreover, the detection results are obtained in short delay without the need for highly technical equipment for the readout.Here, we validated a LFIA for the detection of CTX-Ms (from group 1) and to a wider extent evaluated the direct detection of CTX-Ms from groups 1, 2, 8 and 9 in clinical samples such as blood culture and urine. Mono-tests to detect NDMs and OXA-48-like, and a multiplex for the simultaneous detection of the five main carbapenemases were also validated. These validations were conducted using 180 well characterized isolates in terms of their -lactamase content from the French National Reference Centre for carbapenem-resistant Enterobacteriaceae
Decamps, Sophie. "Synthèse d'inhibiteurs fluorés de carbapénémases : combattre la résistance aux antibiotiques des bactéries à Gram négatif". Thesis, Paris 11, 2015. http://www.theses.fr/2015PA114807.
Texto completo da fonteMultidrug resistant gram-negative pathogens are emerging worldwide. β-lactamases production, especially carbapenemases, enzymes with broad hydrolytic capabilities towards β-lactams, is a global spread mechanism of resistance among gram-negative bacteria. We report here the design and the synthesis of new fluorinated inhibitors of carbapenemases. Our aim was to synthesize trifluoromethylated monobactams in C4 position. We have developed a new diastereoselective pathway by ring expansion of aziridines to access to 3-bromo-4-CF3-azetidin-2-ones. These compounds have been successfully functionalized in C3 position via nucleophilic substitution, radical and organometallic reactions.In a second part, cyclisation attempts of β-hydroxyaminoesters and acids, as well as β-hydroxy-hydroxamates have been conducted. A study of Michael addition of hydroxylamines on trifluoromethylated Michael acceptors have been achieved in order to obtain the β-hydroxyaminoesters and acids derivatives.Finally, biological evaluations of synthesized compounds have been realized through enzymatic tests. 19F NMR evaluation have been accomplished and led to development of diagnostic and screening tools, and it is still in under optimisation
Guillon, Hélène. "Activité carbapénémase des β-lactamases de type AmpC". Amiens, 2013. http://www.theses.fr/2013AMIED003.
Texto completo da fonteOwing to several clinical reports, it appears that AmpC-type β-lactamases (cephalosporinases) account frequently for carbapenem resistance in Enterobacteriaceae. The aim of this study was to perform a phenotypic, biochemical, and molecular characterization of the carbapenem-hydrolyzing activity of AmpC-type β-lactamases. First of all, the genes encoding the five main plasmid-mediated AmpC β-lactamases were cloned and transferred into the porin-deficient Escherichia coli HB4 strain. Phenotypic and molecular comparison of the recombinant strains revealed that only CMY-2, ACT-1, and DHA-1 conferred resistance to carbapenems and had an asparagine residue at position 346 (Asn 346), located in the vicinity of the active site. Site-directed mutagenesis experiments were performed to replace the Asn 346 residue of CMY-2 β-lactamase by amino acids differing in size, charge, and polarity. It confirmed the contribution of Asn 346 to the carbapenem-hydrolysing activity of cephalosporinases. Biochemical characterization of three variants revealed that Asn 346 assisted the binding of imipenem. The analysis of the carbapenem-hydrolyzing activity of chromosomal extended-spectrum AmpC β-lactamases (ESAC) constitutes the second part of this thesis. Sequencing, cloning and biochemical characterization of a novel ESAC produced by an ertapenem-resistant E. Coli clinical isolate demonstrated that the extension of the hydrolysis spectrum of cephalosporinases, which was due to increased affinity, may also contribute to carbapenem resistance
Chaslus-Dancla, Elisabeth. "Etude épidémiologique de bactéries résistantes aux antibiotiques en élevages intensifs". Lyon 1, 1987. http://www.theses.fr/1987LYO19019.
Texto completo da fonteSevaille, Laurent. "Inhibition de métallo-B-lactamases (MBLs) pour lutter contre la résistance bactérienne aux antibiotiques". Thesis, Montpellier, 2018. http://www.theses.fr/2018MONTS136.
Texto completo da fonteThe spread of multiresistant Gram negative bacteria is a growing threat to public health and the risk of return to the pre-antibiotic era is real. Among existing resistance modes, the production of metallo-B-lactamases (MBLs) responsible of the inactivation of B-lactams, the most used family of antibiotics, represents a therapeutical challenge.This manuscript describes the synthesis, characterization and biological evaluation of compounds built on a 2,4-dihydro-3H-1,2,4-triazole-3-thione scaffold substituted on two positions. Based on previous in silico screening and crystallographic studies, which identified this structure as a good candidate for MBLs inhibition, several series have been developed to found new inhibitors that could potentially be amenable to clinical development.First, 1,2,4-triazole-3-thione compounds substituted at position 5 have been prepared following classical pathways. Then, several series have been developed where the structural and functional diversity was introduced at position 4. Compounds have been tested on representative MBLs of the three sub-classes and the most interesting ones on recombinant resistant bacteria.To perform a rapid screening of compounds in the laboratory, a method of medium throughput screening inhibition tests on five MBLs performed in 96-wells plate has also been developed and validated during this study with the help of our collaborators specialists of MBLs
Saves, Isabelle. "Evolution de la béta-lactamase TEM-1". Toulouse 3, 1995. http://www.theses.fr/1995TOU30206.
Texto completo da fonteWackenaer-Descleves, Estelle. "Les β-lactamases chromosomiques des Raoultella spp : support pour la résistance aux antibiotiques et outils de diagnostic étiologique". Paris 5, 2008. http://www.theses.fr/2008PA05T037.
Texto completo da fonteThe three species of Raouliellu (formerly Klebsiella). R. Planticola (Rp), R. Ornithinolytica (Ro) and R. Terrigena (Rt) cannot be distinguished from the species of Klebsiella spp. By the tests used in the routine by microbiological laboratories. After having (i) cloned the p-lactamases of the 3 Raoultella species (PLA, ORN and TER), (ii) evaluated the percentage of identity between each other (94% between PLA and ORN, and 78% with TER) and with other class A P-lactamases (70% with TEM-1, 68% with SHV-1 and 38% with KOXY), and (iii) studied the p-lactamase activity of PLA and TER, the reliability of the bla gene for Rp and Ro identification was determined in comparison with that of the 16S rDNA and rpoB genes in 35 Raoultella spp. Isolates. This study allowed us to discover that 70% of the isolates identified as Ro were negative for the ornithine decarboxylase test, meaning negative for the biochemical character on which Ro definition was based, and to develop a new test, bla RFLP. To unambiguously identify Ro and Rp
Mhaya, Amel. "Analyse de la résistance aux antibiotiques chez les entérobactéries et étude d’une potentielle voie alternative aux traitements antibiotiques". Thesis, Bordeaux, 2019. http://www.theses.fr/2019BORD0420.
Texto completo da fonteThe increase of multidrug-resistant bacteria (BMR) to antibiotics is a major public health problem. The first objective of the thesis was to search for the presence of BMR, poorly documented in the community in Tunisia. For the first time, we isolate a Klebsiella pneumoniae belonging to the sequence type ST147 producing carbapenemase NDM-1 in this setting, at Sfax. Our data also indicate an unusually high proportion (47%) of Escherichia coli producing committally two extended-spectrum ß-lactamases. Four of them, with CTX-M-15 and CTX-M-27, are divided into 2 clonal strains of type A-ST617 (2 isolates) and B2-ST131 subclade C2 (2 isolates). All contain a plasmid with the same allelic combination, F31: A4: B1; suggesting a possible dissemination of this replicon. In another study (community-based, Djerba), a multiresistant clonal strain Eh22 of Enterobacter hormaechei, containing a 300 kbp conjugative plasmid of IncHI2, was isolated from 2 patients without apparent epidemiological relationship. The plasmid was sequenced and shows the presence of different resistance genes including 4 genes encoding β-lactamases (blaTEM-1, blaDHA-1, blaCTX-M-3 and blaSHV-12). In a second part, we studied in Eh22, the resistance to colistin (CS), antibiotic of last resort. After selection of an in vitro mutant, we showed for the first time, in Enterobacter spp, that this resistance can be due to a mutation in the gene encoding MgrB, a negative regulator of the 2-component PhoQP system that allows the synthesis of cationic residues on lipopolysaccharide, target of CS. In the last part, bacteriocins-like molecules active on BMR were searched in a collection of Bacillus thurengiensis. One of them, BUPM103, inhibits the growth of BMR. The gene for a potential bacthuricin F103 (11 kDa) was identified by an in silico analysis and it was produced in E. coli. The filtered supernatant secretion showed a growth inhibitory activity against a multiresistant K. pneumoniae, in contrast to control (without secretion). This recombinant bacthuricine could constitute a therapeutic alternative for the BMR treatment